GlaxoSmithKline (GSK) Tops Q4 EPS by 4p

GlaxoSmithKline (NYSE: GSK) reported Q4 EPS of GBP0.31, GBP0.04 better than the analyst estimate of GBP0.27. Revenue for the quarter came in at GBP8.2 billion versus the consensus estimate of GBP7.98 billion.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
• SanDisk and Micron surge as Apple confirms memory price pass-through
• Hyperscale Data launches $300M at-the-market stock offering